Specialty Pharmacy Continuum

1 week ago | specialtypharmacycontinuum.com | Marie Rosenthal

Originally published by our sister publication Infectious Disease Special EditionBy Marie Rosenthal, MSIf given within 72 hours after clinical onset of COVID-19 in a household, oral ensitrelvir was effective in protecting household contacts from SARS-CoV-2 infection, according to a presentation at ESCMID Global 2025, in Vienna (abstract 03159). Protection was consistently seen in all at-risk groups studied, including older household contacts, according to Frederick G. Hayden, MD, the Stuart S.

2 weeks ago | specialtypharmacycontinuum.com | Kate Baggaley

Several campaigns aimed at addressing burnout among healthcare workers and strategies for promoting pharmacist well-being at an organizational level were highlighted at the ASHP Midyear 2024 Clinical Meeting & Exhibition, in New Orleans. Speakers emphasized that the onus should not be on individual pharmacists to make themselves more resilient.

1 month ago | specialtypharmacycontinuum.com | Marie Rosenthal

Originally published by our sister publication Infectious Disease Special EditionBy Marie Rosenthal, MSA long-term HIV survivor, Rebecca Denison said healthcare professionals should make sure that people living with HIV understand they can live normal lives that include meaningful work, having families and loving relationships. But such a life does not come without challenges.

1 month ago | specialtypharmacycontinuum.com | Chase Doyle |Sarah Tilyou

Originally published by our sister publication Gastroenterology & Endoscopy NewsBy Chase Doyle and Sarah TilyouDENVER—Despite two decades of progress in ablation techniques, the incidence of esophageal cancer has remained largely unchanged, prompting some experts to reevaluate their approach to management of Barrett’s esophagus. In a presentation at the 2024 annual meeting of the American Foregut Society.

1 month ago | specialtypharmacycontinuum.com | Marie Rosenthal

Originally published by our sister publication Infectious Disease Special Edition By Marie Rosenthal, MS More data from the STOMP (Study of Tecovirimat for Mpox) trial presented at CROI 2025, held in San Francisco, confirm that tecovirimat does not reduce the time to clinical resolution of clade II mpox lesions or improve pain among adults, according to Timothy Wilkin, MD, MPH, a professor of medicine and the chief of the Division of Infectious Diseases and Global Public Health at the...